Found 2 results
Biomarkers Are Not Drug Targets, and Why That Distinction Costs the Industry Billions
Why conflating biomarkers with drug targets leads to failed trials and billions lost. A deep dive into causal cell-state pharmacology.
Biomarkers Are Not Drug Targets, and Why That Distinction Costs the Industry Billions
If one assumption has quietly cost pharmaceutical R&D more than any other in the past two decades, it is the conflation of biomarker with drug target. They look similar on a slide. They diverge sharply in clinical trials.